Condition: Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer · Sponsor: National Cancer Centre, Singapore
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies. This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.
This description comes directly from the study's public registry record.
Cherlyn Shepherdson · +65 6306 1748 · cherlyn.shepherdson@nccs.com.sg
Always discuss trial participation with your own doctor first.
| National Cancer Centre, Singapore | Singapore, Singapore | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06418412